Third Time's The Charm: Outlook Therapeutics' Lytenava Heads To FDA, Again

Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...
SurvivorNet on MSN

Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
Santé log

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S.
Engadget

CES 2026: What to expect when tech's biggest conference starts on January 4

The new year is upon us, and that means CES 2026 is imminent. The biggest tech trade show of the calendar comes with a bevy of new and notable announcements that set the tone for trends and ...
Barron's

The U.S. Economy Looks Stable for 2026—and You’ll Feel Better About It, Too

The U.S. economy is expected to grow by 1.8% this year, notwithstanding policy shifts that have flummoxed economists and business leaders. Next year could look much the same, with growth in gross ...
Ophthalmology Times

Q&A: What changed in residency education in 2025? Perspectives from training directors

Chris R. Alabiad, MD: There wasn’t one single national rule change in 2025 that transformed residency training overnight.
Ophthalmology Times

FDA approvals in 2025: What changed and why it matters for ophthalmologists

FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...